C
CRISPR Therapeutics AG (CRSP)
NGM – Real Time Price. Currency in USD
52.83
-1.18 (-2.18%)
At close: May 12, 2026, 4:00 PM EDT
53.00
+0.17 (0.32%)
Pre-market: May 13, 2026, 7:30 AM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
52.83
-1.18 (-2.18%)
At close: May 12, 2026, 4:00 PM EDT
53.00
+0.17 (0.32%)
Pre-market: May 13, 2026, 7:30 AM EDT
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company’s CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company’s lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient’s hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
| Name | Position |
|---|---|
| Dr. Chad A. Cowan Ph.D. | Scientific Founder |
| Dr. Craig C. Mello Ph.D. | Scientific Founder & Advisory Board Member |
| Dr. Daniel G. Anderson Ph.D. | Scientific Founder & Advisory Board Member |
| Dr. Emmanuelle Marie Charpentier Ph.D. | Co-Founder & Scientific Advisory Board Member |
| Dr. Matthew Porteus M.D., Ph.D. | Scientific Founder & Advisory Board Member |
| Dr. Naimish Patel C.M., M.D. |
| Date | Type | Document |
|---|---|---|
| 2026-05-04 | 8-K | crsp-20260504.htm |
| 2026-05-04 | 10-Q | crsp-20260331.htm |
| 2026-04-21 | ARS | 2025_ars_for_2026_proxy.pdf |
| 2026-04-02 | PRE 14A | crsp-20260402.htm |
| 2026-03-16 | 8-K | crsp-20260316.htm |
| 2026-03-11 | 8-K | crsp-20260310.htm |
| 2026-02-12 | 10-K | crsp-20251231.htm |
| 2026-01-12 | 8-K | crsp-20260112.htm |
| 2025-11-10 | 8-K | crsp-20251110.htm |
| 2025-10-15 | 8-K | crsp-20251015.htm |
| Chief Medical Officer |
| Dr. Raju Yashaswi Prasad Ph.D. | Chief Financial Officer |
| Dr. Samarth Kulkarni Ph.D. | CEO & Chairman |
| Mr. James R. Kasinger J.D. | General Counsel & Secretary |
| Mr. Shaun Foy CFA | Co-Founder |